Elementis (ELM) investor relations material

Executive summary

• Achieved strong H1 2026 results with 4.7% organic constant currency revenue growth to $318.2m and adjusted operating profit up 16.4% to $73.2m, with margins reaching 23%.

• Completed sale of pharmaceutical manufacturing business, started share buyback, and acquired Alchemy, a high-margin skincare business, sharpening focus as a pure-play specialty chemicals leader.

• Transformation strategy 'Elevate Elementis' is delivering on growth, customer focus, and operational simplification.

• Confident in meeting full-year 2026 expectations despite macroeconomic uncertainties.

Financial highlights

• Revenue up 9.4% reported and 4.7% organic constant currency to $318.2m year-over-year.

• Adjusted operating profit up 16.4% to $73.2m; adjusted EPS up 28.8% to 8.5 cents.

• Margins improved by 140 basis points to 23.0%.

• Free cash flow generation remained strong; net debt reduced to $163.8m (1.1x leverage).

• Interim dividend of 1.5 cents per share approved, up 15.4% year-over-year.

Outlook and guidance

• Confident in meeting full-year 2026 expectations and medium-term targets: mid-single digit organic revenue growth, adjusted operating margin above 23%, operating cash conversion above 90%, and ROCE above 30%.

• Order book into Q3 is solid; cautious approach maintained due to external environment.

• Margins expected to moderate in H2 due to typical seasonal weighting.

• Vigilant regarding potential impacts from the Middle East crisis on demand, costs, and supply chains.